Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Nuwellis, Inc. entered into Common Stock Warrant Agreement with DaVita Inc. valued at warrant to purchase up to an aggregate of 1,289,081 shares of common stock at an exercise price of $ (effective 2023-06-19).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- DaVita Inc.
- Value
- warrant to purchase up to an aggregate of 1,289,081 shares of common stock at an exercise price of $
- Effective
- 2023-06-19
Exact text from the filing
In conjunction with the Supply Agreement, the Company issued DaVita a warrant to purchase up to an aggregate of 1,289,081 shares of common stock of the Company, par value $0.0001 per share, at an exercise price of $3.2996 per share, provided that at no time can it be exercised for an amount of shares that would represent greater than 19.9% ownership in the Company (the “ Warrant ”) subject to certain vesting milestones.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Nuwellis, Inc. entered into Registration Rights Agreement with DaVita Inc. valued at Company agreed to register the resale of the shares of Common Stock issuable upon exercise of the Wa (effective 2023-06-19).
- Action
- entry
- Agreement
- supply
- Counterparty
- DaVita Inc.
- Value
- Company agreed to register the resale of the shares of Common Stock issuable upon exercise of the Wa
- Effective
- 2023-06-19
Exact text from the filing
Concurrent with the signing of the Supply Agreement and Warrant, the Company entered into a Registration Rights Agreement (“ Registration Rights Agreement ”) with DaVita, whereby the Company agreed, subject to DaVita’s delivery of the Ultrafiltration Services Approval, to register the resale of the shares of Common Stock issuable upon exercise of the Warrant (“ Underlying Shares ”) on a Form S-1 or Form S-3, if eligible, upon DaVita’s demand.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Nuwellis, Inc. entered into Supply and Collaboration Agreement with DaVita Inc. valued at DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive (effective 2023-06-19).
- Action
- entry
- Agreement
- supply
- Counterparty
- DaVita Inc.
- Value
- DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive
- Effective
- 2023-06-19
Exact text from the filing
On June 19, 2023, Nuwellis, Inc. (the “ Company ”) entered into a Supply and Collaboration Agreement (the “ Supply Agreement ”) with DaVita Inc., a Delaware corporation (“ DaVita ”), pursuant to which DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive heart failure and related conditions within select U.S. markets .
View on SEC.gov